Seres Therapeutics, Inc.
MCRB
$17.03
$0.331.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -87.61% | 314.74% | |||
| Gross Profit | 90.01% | -314.74% | |||
| SG&A Expenses | -7.58% | -13.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.25% | -8.65% | |||
| Operating Income | 9.66% | 8.65% | |||
| Income Before Tax | 141.32% | -160.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 141.32% | -160.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 141.32% | -160.75% | |||
| EBIT | 9.66% | 8.65% | |||
| EBITDA | 10.03% | 8.94% | |||
| EPS Basic | 141.25% | -160.47% | |||
| Normalized Basic EPS | 5.26% | -2.30% | |||
| EPS Diluted | 141.25% | -160.55% | |||
| Normalized Diluted EPS | 5.40% | -2.44% | |||
| Average Basic Shares Outstanding | 0.17% | 0.47% | |||
| Average Diluted Shares Outstanding | 0.32% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||